https://www.selleckchem.com/pr....oducts/3-methyladeni
34-9.09) were risk factors for CRLM. Group A had a significantly better 5-year liver disease-free survival than group B (P = 0.011, HR = 0.31, 95% CI 0.16-0.63), but there was no significant difference in the 5-year overall survival (P = 0.433). HBV infection may reduce the risk of metachronous liver metastasis in stage 2 colorectal cancer. HBV infection may reduce the risk of metachronous liver metastasis in stage 2 colorectal cancer. The aim of this study was to clarify the surgical supply situation of oncological colorectal p
Like
Comment
Share
